Microbot Med Inc Stock Price, News & Analysis

Microbot Medical (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic System, has been added to the Russell Microcap® Index effective June 30, 2025. The inclusion comes at a strategic time as the company prepares for the anticipated Q3 launch of LIBERTY, which is currently pending FDA 510(k) clearance.

The Russell Microcap® Index is part of the annual Russell US Indexes reconstitution, which captures the 4,000 largest US stocks based on market capitalization. Russell indexes serve as benchmarks for approximately $10.6 trillion in assets as of June 2024, and are widely used by investment managers and institutional investors.

Microbot Medical (NASDAQ: MBOT) has secured a significant patent in China from CNIPA for its LIBERTY Endovascular Robotic System, specifically covering robotic manipulation of surgical tool handles. This addition brings their global patent portfolio to 9 granted patents and 59 pending applications. The company is preparing for LIBERTY's anticipated Q3 2025 U.S. commercial launch, pending FDA clearance. The market opportunity is substantial, with an estimated 2 million peripheral endovascular procedures annually in the U.S. and 2.9 million in China. The patent strengthens Microbot's IP protection and supports their global commercialization strategy, particularly in key markets like China.

Microbot Medical continues to strengthen its commercial capabilities ahead of the anticipated Q3 2025 launch of its LIBERTY Endovascular Robotic System. The company has appointed Michael Lytle as head of Sales Operations & Analytics, bringing extensive experience in sales support and data analysis from ZOLL Cardiac Management Solutions. The FDA's 510(k) decision for the LIBERTY System is now expected in Q3 2025, remaining within the original review window and not affecting the planned launch timeline. CEO Harel Gadot expressed confidence in the FDA process and emphasized the company's continued momentum in building commercial infrastructure. The LIBERTY System is currently under FDA review and not yet available for sales in the US.

Microbot Medical (NASDAQ: MBOT), known for its LIBERTY® Endovascular Robotic System, has been preliminarily selected for inclusion in the Russell Microcap® Index. The inclusion is expected to be effective after market close on June 27, 2025, with active trading beginning June 30, 2025. This addition is part of the 2025 Russell indexes reconstitution, which ranks the 4,000 largest US stocks by market capitalization as of April 30, 2025. The Russell Microcap® Index membership lasts one year and includes automatic inclusion in corresponding growth and value style indexes. The Russell indexes are significant benchmarks in the investment industry, serving as references for approximately $10.6 trillion in assets as of June 2024.

Microbot Medical (Nasdaq: MBOT) has strengthened its commercial leadership team with key appointments ahead of the anticipated LIBERTY® Endovascular Robotic System launch. Allison Rosefort joins as Vice President of Marketing, bringing over 15 years of healthcare marketing experience and a track record of driving double-digit revenue growth. She will oversee downstream marketing and brand management strategies.

The company also welcomed Lisa Dobbins as Director of Human Resources and recently added Paul Mullen as Vice President of Sales. These appointments are strategically timed with the expected FDA decision on LIBERTY® in Q2 2025. The company aims to be prepared for immediate commercial launch following potential FDA clearance.

Rosefort previously served as Senior Director at Topcon Healthcare, while Dobbins joins from Integra LifeSciences where she was HR Business Partner for Global Operations and Quality.

Microbot Medical (NASDAQ: MBOT) has announced groundbreaking results from its ACCESS-PVI pivotal trial for the LIBERTY® Endovascular Robotic System. The trial, conducted at three leading U.S. medical centers, demonstrated a 100% success rate in robotic navigation across all cases (N=20), meeting the study's primary endpoint.

Key achievements include:

• 92% reduction in radiation exposure for operators
• Zero adverse device events reported
• Median robotic navigation time of 3 minutes to target
• 100% physician satisfaction rate

The study was conducted at Memorial Sloan Kettering Cancer Center, Baptist Hospital of Miami, and Brigham and Women's Hospital. The LIBERTY® system is currently pending FDA 510(k) clearance and is not yet available for sale in the U.S.

Microbot Medical (Nasdaq: MBOT) announces that data from its ACCESS-PVI trial for the LIBERTY® Endovascular Robotic System will be presented at the Society of Interventional Radiology Annual Meeting. The presentation will be delivered by Dr. Francois Cornelis from Memorial Sloan Kettering Cancer Center on April 2, 11:33am CT.

The ACCESS-PVI trial is a prospective, multicenter, single-arm study evaluating the performance and safety of LIBERTY® in peripheral vascular interventions. The company's executive and clinical teams are conducting meetings with SIR attendees. Importantly, Microbot Medical reaffirms its expectation for the FDA's decision regarding LIBERTY®'s 510(K) clearance during the current second quarter.

Microbot Medical (Nasdaq: MBOT) has appointed Paul Mullen as Vice President of Sales, marking the company's first commercial hire as it prepares for the anticipated FDA clearance of its LIBERTY® Endovascular Robotic System in Q2 2025.

Mullen, who will report to CEO Harel Gadot, joins from Inari Medical (recently acquired by Stryker for $4.94 billion), where he served as Director of Sales and played a key role in launching breakthrough thrombectomy devices. His experience includes successful launches of devices treating chronic venous disease affecting over 1,000,000 U.S. patients.

Prior roles include positions at Philips Volcano's endovascular division and LeMaitre Vascular, where he managed sales teams and launched multiple technologies. His immediate responsibilities at Microbot Medical will focus on building sales strategy and infrastructure for the LIBERTY® system launch.

Microbot Medical Inc. (NASDAQ: MBOT) announced a significant milestone in its collaboration with Corewell Health™ on robotic telesurgery for endovascular applications. Research demonstrating the feasibility of using the LIBERTY® Endovascular Robotic System between separate facilities 5 miles apart in a coronary simulation model has been accepted for presentation at the Cardiovascular Research Technologies (CRT) annual meeting on March 10, 2025.

The study, led by Dr. Ryan Madder, Section Chief of Interventional Cardiology at Corewell Health™, will be presented by Dr. Trisha Gomez and published in the Journal of the American College of Cardiology (JACC) Interventions. Dr. Madder noted that the LIBERTY® system "functioned well in a telerobotic setting" with its small footprint and disposable design creating "exciting possibilities for future telerobotic endovascular procedures."

Microbot's CEO Harel Gadot emphasized that telesurgery capabilities are an important part of their long-term strategy, potentially increasing access to quality healthcare for patients in remote locations. The telesurgery feature is still under development and not covered under Microbot's pending 510(k) submission with the FDA.